Urology · Memphis, TN
NPI
1184739401
Since 2006
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
995 S Yates Rd, Ste. 1
Memphis, TN, 38119
Phone (901) 527-7100
Groups this clinician bills Medicare through
Medicare paid, 2024
$677K
9,466 services
Medicare patients, 2024
787
Average age 76
Drug cost, 2024
$7.1M
2,648 prescriptions
Company payments, 2025
$6,131
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark J Saslawsky was code 81003 (clinical chemistry), 1,142 times for 639 patients. In total Mark J Saslawsky billed 9,466 services in 80 codes, and Medicare paid $677K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-11-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 81003 Clinical Chemistry | Office | 1,142 | 639 | $2.19 | $2,496 |
| 82570 Clinical Chemistry | Office | 1,142 | 639 | $5.05 | $5,768 |
| 82044 Clinical Chemistry | Office | 1,142 | 639 | $6.07 | $6,937 |
| 36415 Venipuncture Blood Collection | Office | 925 | 537 | $8.59 | $7,944 |
| 99213 Office E&M - Established | Office | 800 | 485 | $56.14 | $45K |
| 51798 Ultrasound - Nonspecific | Office | 757 | 504 | $6.75 | $5,111 |
| 51741 Test - Miscellaneous | Office | 632 | 436 | $8.72 | $5,514 |
| 99214 Office E&M - Established | Office | 493 | 325 | $81.15 | $40K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 403 | 54 | $33.32 | $13K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 396 | 48 | $139.44 | $55K |
| 76770 Ultrasound - Abdomen and Pelvis | Office | 236 | 170 | $67.17 | $16K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 207 | 54 | $44.09 | $9,126 |
| 99489 Chronic, Principal, and Transitional Care Management | Office | 185 | 31 | $51.48 | $9,523 |
| 96402 Chemotherapy Administration | Office | 131 | 49 | $24.49 | $3,208 |
| 99233 Hospital E&M - Subsequent | Facility | 92 | 64 | $84.36 | $7,761 |
By year: 2022 $323K for 15,515 services; 2023 $310K for 9,924 services; 2024 $677K for 9,466 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 1,142 | 639 | $2.19 | $2,496 |
| 82044 Clinical Chemistry | 1,142 | 639 | $6.07 | $6,937 |
| 82570 Clinical Chemistry | 1,142 | 639 | $5.05 | $5,768 |
| 36415 Venipuncture Blood Collection | 925 | 537 | $8.59 | $7,944 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark J Saslawsky prescribed most often to Medicare patients was Tamsulosin Hcl, with 557 prescriptions and refills. In total Mark J Saslawsky wrote 2,648 Medicare prescriptions that cost $7.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 557 | 1,565 | 180 | $8,146 |
| Finasteride Generic | 475 | 1,415 | 154 | $7,747 |
| Xtandi Enzalutamide | 340 | 340 | 34 | $4.6M |
| Oxybutynin Chloride Er Oxybutynin Chloride | 122 | 286 | 50 | $2,536 |
| Erleada Apalutamide | 120 | 120 | 18 | $1.7M |
| Dutasteride Generic | 104 | 268 | 29 | $2,654 |
| Orgovyx Relugolix | 80 | 80 | 14 | $205K |
| Xgeva Denosumab | 68 | 68 | Under 11 | $213K |
| Terazosin Hcl Generic | 57 | 167 | 16 | $781 |
| Ciprofloxacin Hcl Generic | 54 | 54 | 45 | $228 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 49 | 51 | 43 | $752 |
| Nitrofurantoin Nitrofurantoin Macrocrystal | 43 | 43 | 31 | $786 |
| Levofloxacin Generic | 43 | 43 | 33 | $89.18 |
| Myrbetriq Mirabegron | 43 | 87 | 13 | $39K |
| Megestrol Acetate Generic | 42 | 64 | 15 | $1,155 |
Brand drugs: 743 claims; generic drugs: 1,905 claims; opioid claims: 40.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark J Saslawsky $6,131 ($6,131 in general payments such as food, travel and fees) from 28 companies. The largest payer was Janssen Biotech, Inc. with $2,125.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.